| 2025-11-03 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.2美元,归母净利润-6860万美元,同比去年增长92.34%
|
| 2025-11-03 |
财报披露：
美东时间 2025-11-03 盘前发布财报
|
| 2025-09-26 |
详情>>
股本变动：
变动后总股本34979.13万股
变动原因 ▼▲
- 原因：
- 20250101-20250630
根据2022年股份激励计划发行A类普通股
发行普通股后续公开发行
将普通股从B类重新指定为A类
回购普通股
|
| 2025-09-26 |
详情>>
业绩披露：
2025年中报每股收益-0.2美元,归母净利润-6905.6万美元,同比去年增长87.90%
|
| 2025-04-30 |
详情>>
业绩披露：
2025年一季报每股收益-0.57美元,归母净利润-1.88亿美元,同比去年增长33.93%
|
| 2025-03-26 |
详情>>
业绩披露：
2022年年报每股收益-8.02美元,归母净利润-19.2亿美元,同比去年增长-35.31%
|
| 2025-03-26 |
详情>>
业绩披露：
2024年年报每股收益-2.77美元,归母净利润-9.32亿美元,同比去年增长0.84%
|
| 2024-11-07 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.66美元,归母净利润-8.96亿美元,同比去年增长-38.83%
|
| 2024-09-30 |
详情>>
业绩披露：
2024年中报每股收益-1.69美元,归母净利润-5.71亿美元,同比去年增长-49.95%
|
| 2024-05-20 |
详情>>
业绩披露：
2024年一季报每股收益-0.84美元,归母净利润-2.85亿美元,同比去年增长-39.15%
|
| 2024-04-03 |
详情>>
业绩披露：
2023年年报每股收益-2.79美元,归母净利润-9.4亿美元,同比去年增长51.03%
|
| 2023-11-09 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-1.91美元,归母净利润-6.45亿美元,同比去年增长41.82%
|
| 2023-07-03 |
复牌提示：
2023-07-03 11:38:42 停牌，复牌日期 2023-07-03 11:43:42
|
| 2022-12-20 |
详情>>
内部人交易：
COVA Acquisition Sponsor LLC共交易2笔
|
| 2022-11-18 |
股东大会：
将于2022-12-14召开股东大会
会议内容 ▼▲
- 1.To consider and vote upon, as an ordinary resolution, a proposal (the “Business Combination Proposal”) to approve and authorize the Agreement and Plan of Merger (“Merger Agreement”), dated as of May 26, 2022 by and among COVA, ECARX Holdings Inc., a Cayman Islands exempted company (the “Company” or “ECARX”), Ecarx Temp Limited, a wholly-owned subsidiary of ECARX (“Merger Sub 1”), and Ecarx&Co Limited, a wholly-owned subsidiary of ECARX (“Merger Sub 2”), a copy of which is attached to this proxy statement/prospectus as Annex A, and the transactions contemplated therein, including the business combination whereby Merger Sub 1 will merge with and into COVA (the “First Merger”), with COVA surviving the First Merger as a wholly owned subsidiary of ECARX (such company, as the surviving entity of the First Merger, “Surviving Entity 1”), and immediately following the First Merger and as part of the same overall transaction as the First Merger, Surviving Entity 1 will merge with and into Merger Sub 2 (the “Second Merger,” and together with the First Merger, the “Mergers”), with Merger Sub 2 surviving the Second Merger as a wholly-owned subsidiary of ECARX (such company, as the surviving entity of the Second Merger, “Surviving Entity 2”) (collectively, the “Business Combination”);
2.To consider and vote upon, as a special resolution, a proposal (the “Merger Proposal”) to approve and authorize the First Merger and the First Plan of Merger, substantially in the form attached to this proxy statement/prospectus as Annex C;
3.To consider and vote upon, as an ordinary resolution, a proposal (the “Adjournment Proposal”) to adjourn the extraordinary general meeting to a later date or dates to be determined by the chairman of the extraordinary general meeting, if necessary, to permit further solicitation and vote of proxies if, based upon the tabulated vote at the time of the extraordinary general meeting, there are not sufficient votes to approve one or more proposals presented to shareholders for a vote.
|